News

U.S. Vaccine Panel Reverses Course, Now Emphasizes Doctor-Patient Decision Making for COVID Shots

Vaccine manufacturers Pfizer (in partnership with BioNTech), Moderna, and Sanofi (partnering with Novavax) reaffirmed their trust in the safety and efficacy of their products. Yet the advisory panel’s new direction signals a critical inflection point in U.S. immunization policy: one that puts doctors’ expertise and individualized patient risk assessment at the center of vaccination decisions.

• By Reuters
• Washington
• Sep 24, 2025

News

In a notable departure from previous policy, a U.S. advisory committee has abandoned its blanket recommendation for COVID-19 vaccination across all ages. Instead, it now calls for vaccination decisions to be made through consultation between patients and their physicians.

The committee in question—the Advisory Committee on Immunization Practices (ACIP)—recently convened under the leadership of Health Secretary Robert F. Kennedy Jr. Its newly appointed members voted to shift from an across-the-board mandate to a more individualized approach. Under the new stance, COVID shots would still be available for all ages, but administered based on “shared clinical decision-making” between a patient and healthcare provider.

The vote follows controversial changes in the panel’s membership, many of whom have previously expressed skepticism about routine vaccination or raised concerns about COVID shot safety. Five new members began their terms just prior to this shift.

During deliberations, some members cited emerging safety issues that warrant more in-depth study. Their arguments prompted the panel to reconsider prior assumptions about universal COVID immunization. In parallel, the committee also moved to restrict use of the combined MMRV (measles, mumps, rubella, varicella) vaccine in children under four years old, signaling a broader reevaluation of childhood vaccine policy.

The U.S. Centers for Disease Control and Prevention (CDC), meanwhile, presented data supporting the effectiveness and safety of COVID vaccines—highlighting reductions in emergency department visits among children and declines in serious illness among seniors aged 65 and above.

Vaccine manufacturers Pfizer (in partnership with BioNTech), Moderna, and Sanofi (partnering with Novavax) reaffirmed their trust in the safety and efficacy of their products. Yet the advisory panel’s new direction signals a critical inflection point in U.S. immunization policy: one that puts doctors’ expertise and individualized patient risk assessment at the center of vaccination decisions.